We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+3.27%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$7.23B
AUM Growth
+$298M
(+4.3%)
Cap. Flow
+$149M
Cap. Flow
% of AUM
2.07%
Top 10 Holdings %
Top 10 Hldgs %
15.39%
Holding
1,100
New
151
Increased
415
Reduced
333
Closed
164
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$40.6M |
| 2 |
Autodesk
ADSK
|
+$38.8M |
| 3 |
Intuit
INTU
|
+$37.1M |
| 4 |
Ecolab
ECL
|
+$35.6M |
| 5 |
Coca-Cola
KO
|
+$35.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$51.9M |
| 2 |
EOG Resources
EOG
|
+$33.8M |
| 3 |
DATA
Tableau Software, Inc.
DATA
|
+$32M |
| 4 |
Microsoft
MSFT
|
+$29.8M |
| 5 |
Ford
F
|
+$29.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.67% |
| 2 | Financials | 17.68% |
| 3 | Consumer Discretionary | 13.74% |
| 4 | Industrials | 11.53% |
| 5 | Healthcare | 11.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
526
Archrock
AROC
$6.33B
| $1.96M | 0.03% |
+184,534
| New | +$1.81M |
|
527
Citigroup
C
$222B
| $1.95M | 0.03% |
+27,810
| New | +$1.86M |
|
528
Rigel Pharmaceuticals
RIGL
$680M
| $1.94M | 0.03% |
74,293
+9,390
| +14% | +$212K |
|
529
Digi International
DGII
$2.52B
| $1.93M | 0.03% |
152,253
+34,140
| +29% | +$415K |
|
530
Forrester Research
FORR
$172M
| $1.92M | 0.03% |
+40,731
| New | +$1.96M |
|
531
Axsome Therapeutics
AXSM
$12.4B
| $1.91M | 0.03% |
74,265
| – | – |
|
|
SNCR
532
DELISTED
Synchronoss Technologies
SNCR
| $1.91M | 0.03% |
26,808
-4,330
| -14% | -$244K |
|
|
HAPN
533
Happen Inc
HAPN
$2.08B
| $1.91M | 0.03% |
116,221
-33,345
| -22% | -$526K |
|
|
AMED
534
DELISTED
Amedisys
AMED
| $1.9M | 0.03% |
+15,660
| New | +$1.86M |
|
|
TYPE
535
DELISTED
Monotype Imaging Holdings Inc.
TYPE
| $1.86M | 0.03% |
110,310
-16,038
| -13% | -$286K |
|
536
Enova International
ENVA
$5.91B
| $1.84M | 0.03% |
80,001
-40,217
| -33% | -$964K |
|
|
MEET
537
DELISTED
The Meet Group, Inc. Common Stock
MEET
| $1.84M | 0.03% |
528,615
+66,820
| +14% | +$297K |
|
538
Wabash National
WNC
$543M
| $1.83M | 0.03% |
112,360
+83,060
| +283% | +$1.22M |
|
|
DLPH
539
DELISTED
Delphi Technologies PLC Ordinary Shares
DLPH
| $1.83M | 0.03% |
91,320
+1,450
| +2% | +$29.7K |
|
|
CPLG
540
DELISTED
CorePoint Lodging Inc. Common Stock
CPLG
| $1.82M | 0.03% |
147,217
+30,400
| +26% | +$385K |
|
541
Deckers Outdoor
DECK
$13.3B
| $1.81M | 0.03% |
+61,860
| New | +$1.61M |
|
542
Charles River Laboratories
CRL
$10.9B
| $1.81M | 0.03% |
12,776
-100
| -0.8% | -$13.6K |
|
|
TNAV
543
DELISTED
Telenav Inc.
TNAV
| $1.81M | 0.03% |
225,856
+100,904
| +81% | +$703K |
|
|
CHX
544
DELISTED
ChampionX
CHX
| $1.8M | 0.03% |
53,802
+20,620
| +62% | +$749K |
|
545
State Street SPDR S&P MIDCAP 400 ETF Trust
MDY
$27B
| $1.8M | 0.02% |
5,080
| – | – |
|
546
Foster
FSTR
$443M
| $1.74M | 0.02% |
63,621
+39,294
| +162% | +$899K |
|
547
Medpace
MEDP
$16.8B
| $1.73M | 0.02% |
26,416
-4,880
| -16% | -$281K |
|
548
Unifirst Corp
UNF
$5.32B
| $1.71M | 0.02% |
9,042
+1,100
| +14% | +$178K |
|
549
Liberty Latin America Class C
LILAK
$1.5B
| $1.7M | 0.02% |
115,269
+6,309
| +6% | +$103K |
|
550
Berkshire Hathaway Class B
BRK.B
$1.07T
| $1.69M | 0.02% |
7,932
+2,030
| +34% | +$420K |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q2 2019 Portfolio in Review
As of Q2 2019, Jacobs Levy Equity Management held 1,100 positions worth $7.23B, up 4.3% from $6.93B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Jacobs Levy Equity Management's Q2 2019 filing shows 151 new, 415 increased, 333 reduced and 164 closed positions. Its largest new stake was Biogen: 175,817 shares worth $41.1M. The largest sale was Allergan plc, an estimated $51.9M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
- Jacobs Levy Equity Management's largest Q2 2019 buy was Biogen: 175,817 shares worth $41.1M.
- Jacobs Levy Equity Management added most to Ecolab in Q2 2019, an estimated $35.6M increase.
- Jacobs Levy Equity Management's biggest Q2 2019 reduction was EOG Resources, cutting an estimated $33.8M.
- Jacobs Levy Equity Management fully exited Allergan plc in Q2 2019, selling an estimated $51.9M.
- Jacobs Levy Equity Management's ten largest holdings make up 15% of its $7.23B portfolio in Q2 2019.
- Jacobs Levy Equity Management opened 151 new positions and closed 164 in Q2 2019.
- Jacobs Levy Equity Management's portfolio value rose 4.3% quarter-over-quarter to $7.23B.
Based on Jacobs Levy Equity Management's 13F filing for Q2 2019, filed 13 Aug 2019.